Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment

Journal of Virology

Volumn 85, Issue 5, 2011, Pages 2189-2200

  Imbeault, Michaël ^a   Ouellet, Michel ^a   Giguère, Katia ^a   Bertin, Jonathan ^a   Bélanger, Dave ^a   Martin, Geneviève ^a   Tremblay, Michel J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

A20 PROTEIN; ACTIVATION INDUCED CYTIDINE DEAMINASE; AMPHOTERICIN B DEOXYCHOLATE; B7 ANTIGEN; CD23 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND AGONIST; CHEMOKINE RECEPTOR; FAS ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOTOXIN; LYMPHOTOXIN BETA; MACROPHAGE DERIVED CHEMOKINE; MITOGEN ACTIVATED PROTEIN 2 KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TNIP1 PROTEIN; TRANSCRIPTION FACTOR NFKB1; TRANSCRIPTION FACTOR NFKBIA; TRANSCRIPTION FACTOR NFKBIE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL ISOLATION; CONTROLLED STUDY; ENZYME ANALYSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNODETECTION; IMMUNOMODULATION; IMMUNOSTIMULATION; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN MICROARRAY; SECOND MESSENGER; T LYMPHOCYTE ACTIVATION; TONSIL; VIRION;

B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CELLS, CULTURED; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; LYMPHOCYTE ACTIVATION; MALE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79551707880     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01993-10     Document Type: Article

References (58)

1. Adachi, A., et al. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291. (Pubitemid 16013975)
2. Baker, S. J., and E. P. Reddy. 1998. Modulation of life and death by the TNF receptor superfamily. Oncogene 17:3261-3270.
3. Berek, C., and M. Ziegner. 1993. The maturation of the immune response. Immunol. Today 14:400-404.
4. Bishop, G. A., and B. S. Hostager. 2001. Signaling by CD40 and its mimics in B cell activation. Immunol. Res. 24:97-109.
5. Bounou, S., J. E. Leclerc, and M. J. Tremblay. 2002. Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J. Virol. 76:1004-1014.
6. Brenchley, J. M., et al. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12:1365-1371.
7. Burstein, H. J., and A. K. Abbas. 1991. T-cell-mediated activation of B cells. Curr. Opin. Immunol. 3:345-349.
8. Calderhead, D. M., Y. Kosaka, E. M. Manning, and R. J. Noelle. 2000. CD40-CD154 interactions in B-cell signaling. Curr. Top. Microbiol. Immunol. 245:73-99.
9. Cantin, R., J. F. Fortin, and M. Tremblay. 1996. The amount of host HLA-DR proteins acquired by HIV-1 is virus strain- and cell type-specific. Virology 218:372-381. (Pubitemid 26163831)
10. Chaplin, D. D., and Y. Fu. 1998. Cytokine regulation of secondary lymphoid organ development. Curr. Opin. Immunol. 10:289-297.
11. Chirmule, N., N. Oyaizu, C. Saxinger, and S. Pahwa. 1994. Nef protein of HIV-1 has B-cell stimulatory activity. AIDS 8:733-734.
12. Chong, Y., et al. 2004. Downregulation of CXCR5 in CD27- B cells of HIV-1 infected patients. J. Med. Virol. 73:362-367.
13. Cognasse, F., et al. 2005. Differential downstream effects of CD40 ligation mediated by membrane or soluble CD40L and agonistic Ab: a study on purified human B cells. Int. J. Immunopathol. Pharmacol. 18:65-74.
14. Dennis, G., jr., et al. 2003. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 4:P3.
15. Drayton, D. L., et al. 2002. Lymphocyte traffic in lymphoid organ neogenesis: differential roles of Ltalpha and LTalphabeta. Adv. Exp. Med. Biol. 512:43-48.
16. Drosten, C., et al. 2006. Ultrasensitive monitoring of HIV-1 viral load by a low-cost real-time reverse transcription-PCR assay with internal control for the 5′ long terminal repeat domain. Clin. Chem. 52:1258-1266.
17. Durandy, A. 2003. Activation-induced cytidine deaminase: a dual role in class-switch recombination and somatic hypermutation. Eur. J. Immunol. 33:2069-2073.
18. Epeldegui, M., et al. 2010. CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS One 5:e11448.
19. Fournier, A. M., et al. 2002. Spontaneous secretion of immunoglobulins and anti-HIV-1 antibodies by in vivo activated B lymphocytes from HIV-1-infected subjects: monocyte and natural killer cell requirement for in vitro terminal differentiation into plasma cells. Clin. Immunol. 103:98-109.
20. Fry, T. J., et al. 2001. A potential role for interleukin-7 in T-cell homeostasis. Blood 97:2983-2990.
21. Han, S., B. Zheng, Y. Takahashi, and G. Kelsoe. 1997. Distinctive characteristics of germinal center B cells. Semin. Immunol. 9:255-260.
22. He, B., et al. 2006. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J. Immunol. 176:3931-3941. (Pubitemid 44264370)
23. Kornbluth, R. S., K. Kee, and D. D. Richman. 1998. CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines. Proc. Natl. Acad. Sci. U. S. A. 95:5205-5210.
24. Laman, J. D., E. Claassen, and R. J. Noelle. 1996. Functions of CD40 and its ligand, gp39 (CD40L). Crit. Rev. Immunol. 16:59-108.
25. Lane, H. C., et al. 1983. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 309:453-458.
26. Larson, E. D., and N. Maizels. 2004. Transcription-coupled mutagenesis by the DNA deaminase AID. Genome Biol. 5:211.
27. Lawn, S. D., and S. T. Butera. 2000. Incorporation of HLA-DR into the envelope of human immunodeficiency virus type 1 in vivo: correlation with stage of disease and presence of opportunistic infection. J. Virol. 74:10256-10259.
28. Ledbetter, J. A., et al. 1997. Agonistic activity of a CD40-specific single-chain Fv constructed from the variable regions of mAb G28-5. Crit. Rev. Immunol. 17:427-435.
29. Ledbetter, J. A., L. S. Grosmaire, D. Hollenbaugh, A. Aruffo, and S. G. Nadler. 1994. Agonistic and antagonistic properties of CD40 mAb G28-5 are dependent on binding valency. Circ. Shock 44:67-72.
30. Levesque, M. C., et al. 2009. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med. 6:e1000107.
31. Malaspina, A., et al. 2005. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J. Infect. Dis. 191:1442-1450.
32. Mandl, J. N., et al. 2008. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat. Med. 14:1077-1087.
33. Martin, G., et al. 2007. Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD4+ T cells. J. Virol. 81:5872-5881. (Pubitemid 46847024)
34. Martin, G., and M. J. Tremblay. 2004. HLA-DR, ICAM-1, CD40, CD40L, and CD86 are incorporated to a similar degree into clinical human immunodeficiency virus type 1 variants expanded in natural reservoirs such as peripheral blood mononuclear cells and human lymphoid tissue cultured ex vivo. Clin. Immunol. 111:275-285.
35. Matsumoto, M. 1999. Role of TNF ligand and receptor family in the lymphoid organogenesis defined by gene targeting. J. Med. Investig. 46:141-150.
36. Matsumoto, M., Y. X. Fu, H. Molina, and D. D. Chaplin. 1997. Lymphotoxinalpha-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers. Immunol. Rev. 156:137-144.
37. Matsuyama, T., N. Kobayashi, and N. Yamamoto. 1991. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 5:1405-1417.
38. Medrano, F. J., et al. 1998. Tumor necrosis factor beta and soluble APO-1/Fas independently predict progression to AIDS in HIV-seropositive patients. AIDS Res. Hum. Retrovir. 14:835-843.
39. Moir, S., and A. S. Fauci. 2009. B cells in HIV infection and disease. Nat. Rev. Immunol. 9:235-245.
40. Moir, S., et al. 2008. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J. Exp. Med. 205:1797-1805.
41. Moir, S., et al. 2001. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc. Natl. Acad. Sci. U. S. A. 98:10362-10367.
42. Moir, S., et al. 2003. Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc. Natl. Acad. Sci. U. S. A. 100:6057-6062.
43. Mosmann, T. R. 1994. Cytokine patterns during the progression to AIDS. Science 265:193-194. (Pubitemid 24259912)
44. Müller, F., P. Aukrust, I. Nordoy, and S. S. Froland. 1998. Possible role of interleukin-10 (IL-10) and CD40 ligand expression in the pathogenesis of hypergammaglobulinemia in human immunodeficiency virus infection: modulation of IL-10 and Ig production after intravenous Ig infusion. Blood 92:3721-3729.
45. Napolitano, L. A., et al. 2001. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat. Med. 7:73-79.
46. Notermans, D. W., et al. 2001. Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. AIDS Res. Hum. Retrovir. 17:1003-1008.
47. Quezada, S. A., L. Z. Jarvinen, E. F. Lind, and R. J. Noelle. 2004. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22:307-328.
48. Rieckmann, P., G. Poli, C. H. Fox, J. H. Kehrl, and A. S. Fauci. 1991. Recombinant gp120 specifically enhances tumor necrosis factor-alpha production and Ig secretion in B lymphocytes from HIV-infected individuals but not from seronegative donors. J. Immunol. 147:2922-2927.
49. Shirai, A., M. Cosentino, S. F. Leitman-Klinman, and D. M. Klinman. 1992. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J. Clin. Investig. 89:561-566.
50. Spahn, T. W., and T. Kucharzik. 2004. Modulating the intestinal immune system: the role of lymphotoxin and GALT organs. Gut 53:456-465. (Pubitemid 38241347)
51. Spahn, T. W., M. K. Muller, W. Domschke, and T. Kucharzik. 2006. Role of lymphotoxins in the development of Peyer's patches and mesenteric lymph nodes: relevance to intestinal inflammation and treatment. Ann. N. Y. Acad. Sci. 1072:187-193.
52. Swingler, S., et al. 2008. Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS. Cell Host Microbe 4:63-76. (Pubitemid 351958115)
53. Szaniszlo, P., et al. 2004. Getting the right cells to the array: gene expression microarray analysis of cell mixtures and sorted cells. Cytometry A 59:191-202. (Pubitemid 38736294)
54. van Kooten, C., and J. Banchereau. 2000. CD40-CD40 ligand. J. Leukoc. Biol. 67:2-17.
55. Vyakarnam, A., et al. 1991. Altered production of tumour necrosis factors alpha and beta and interferon gamma by HIV-infected individuals. Clin. Exp. Immunol. 84:109-115.
56. Vyakarnam, A., J. McKeating, A. Meager, and P. C. Beverley. 1990. Tumour necrosis factors (alpha, beta) induced by HIV-1 in peripheral blood mononuclear cells potentiate virus replication. AIDS 4:21-27.
57. Weill, J. C., and C. A. Reynaud. 1996. Rearrangement/hypermutation/gene conversion: when, where and why? Immunol. Today 17:92-97.
58. Weimer, R., et al. 1998. HIV-induced IL-6/IL-10 dysregulation of CD4 cells is associated with defective B cell help and autoantibody formation against CD4 cells. Clin. Exp. Immunol. 111:20-29.